Rhythm Pharmaceuticals : RYTM

RYTM

Stock Data

$81.81

$0.45 (0.55%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Rhythm Pharmaceuticals Inc is a biopharmaceutical company focused on developing treatments for rare neuroendocrine diseases. Its flagship product, IMCIVREE (setmelanotide), targets obesity caused by genetic deficiencies and is in advanced clinical trials. The company, founded in 2008 and based in Boston, Massachusetts, collaborates with several global partners to advance its research and bring new therapies to patients with unmet medical needs. Originally known as Rhythm Metabolic, Inc., it rebranded to its current name in 2015.

All Rhythm Pharmaceuticals Articles

1 Article

Lee Jackson | Feb 19, 2026 at 8:09 AM EST

Here Are Thursday’s Top Wall Street Analyst Research Calls: Analog Devices, Chewy, Credo Technology, eBay, Fiverr, Shopify, Verizon, and More

Pre-Market Stock Futures: Futures are trading lower on Thursday, as Walmart’s forward outlook was disappointing. Risk-on was back on Wednesday,…

Rhythm Pharmaceuticals : RYTM

RYTM

$81.81

All Rhythm Pharmaceuticals Articles

Here Are Thursday’s Top Wall Street Analyst Research Calls: Analog Devices, Chewy, Credo Technology, eBay, Fiverr, Shopify, Verizon, and More

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Warren Buffett’s Parting Gift to Investors Is Crushing the Market 6 Months Later

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

College-Educated Families Earned $242,200 While Others Made $42,200, Here's Why the Gap Widened

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Rhythm Pharmaceuticals : RYTM

RYTM

$81.81

All Rhythm Pharmaceuticals Articles

Here Are Thursday’s Top Wall Street Analyst Research Calls: Analog Devices, Chewy, Credo Technology, eBay, Fiverr, Shopify, Verizon, and More

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Warren Buffett’s Parting Gift to Investors Is Crushing the Market 6 Months Later

Featured Reads

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

College-Educated Families Earned $242,200 While Others Made $42,200, Here's Why the Gap Widened